

MEDIA RELEASE**Contact:**David Lanzetta
Seaside Therapeutics
617-374-9009Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060**Seaside Therapeutics Appoints Dr. Paul Wang to the
Key Position of Vice President, Clinical Development**

CAMBRIDGE, MASS., **September 15, 2008** — Seaside Therapeutics announces the appointment of Paul Wang, MD, to the position of Vice President, Clinical Development. Dr. Wang, a pediatrician, brings significant expertise in disorders affecting child development and behavior, and in pediatric clinical drug development. In this newly created position, Dr. Wang will spearhead Seaside's clinical research and development strategy and lead the Company's collaborative research programs with the National Institute of Health (NIH) and numerous charitable foundations.

Dr. Wang joins Seaside Therapeutics from Pfizer Global Research & Development where he was a Senior Director in Clinical Development. While at Pfizer, Dr. Wang provided clinical leadership for multiple pediatric drug development projects spanning epilepsy, migraine, bipolar disorder, schizophrenia and ADHD. Prior to joining Pfizer, Dr. Wang was a member of the faculty at the University of Pennsylvania and Children's Hospital of Philadelphia, where his research and clinical work focused on children with developmental disabilities, especially those resulting from genetic syndromes.

"We are excited to have Paul join the Seaside team at this point in our development," said Dr. Randall Carpenter, co-founder, President and CEO of Seaside Therapeutics. "Paul's extensive experience in pediatric neurological disorders and pediatric drug development will be extremely valuable to Seaside as we advance multiple clinical programs in fragile X and autism into Phase 2 trials. We look forward to his leadership as we seek to develop therapeutics that improve the lives of patients and their families."

Dr. Wang earned his undergraduate degree at Harvard College, his MD at Yale University School of Medicine and served his residency and chief residency in Pediatrics at the University of Michigan. He completed a research fellowship in Developmental Cognitive Neuroscience at the Salk Institute and a clinical fellowship in Developmental-Behavioral Pediatrics at the Children's Hospital of Philadelphia. Dr. Wang has authored more than 50 peer-reviewed publications in the field of developmental-behavioral pediatrics and has consulted with the Food and Drug Administration and the NIH related to his research and to pediatric drug development. Dr. Wang holds leadership roles in and/or serves on the Society for Developmental-Behavioral Pediatrics, the American Academy of Pediatrics' Committee on Pediatric Research, the editorial board of the Journal of Developmental-Behavioral Pediatrics and the Board of Developmental-Behavioral Pediatrics. He has also served on advisory boards of support organizations for families of children with special needs.

About Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of fragile X syndrome, autism and other disorders of brain development. We are dedicated to translating breakthrough discoveries in neurobiology into therapeutics that improve the lives of patients and their families.